Treats dementia of the Alzheimer's type. ANDA 204609, held by Cadila Pharms Ltd. Donepezil Hydrochloride.
As of Nov 16, 2026, ANDA 204609 (Donepezil Hydrochloride), held by Cadila Pharms Ltd, was first approved by FDA on Sep 19, 2017, with 1 approved supplement and 0 published complete response letters.
Donepezil Hydrochloride Tablets is indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's disease.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 19, 2017 | Original application | Approved | None posted |
| Donepezil Hydrochloride5MG · tablet;oral | Donepezil Hydrochloride | Rx |
| Donepezil Hydrochloride10MG · tablet;oral | Donepezil Hydrochloride | Rx |
| May 20, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 19, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters